Tralokinumab, previously known as LP 0162 and CAT-354, represents a significant treatment for chronic dermatitis. This humanized antibody targets IL-13, a key cytokine involved in the progression of the disorder. Clinical
Tiso was the important research tool for investigating antibody behavior. Particularly its novel composition allows scientists to assess features of immunoglobulin interaction and action mechanisms. Additionally, tisotumab can be utilized
Teclistamab serves as a revolutionary cutting-edge anti-BCMA antibody drug compound, designated JNJ-64007957, demonstrating immense promise in the management of multiple myeloma. This innovative medication operates by specifically binding BCMA, a protein highly present on the surface of myelom